Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence

Katherine M. Feeney and Joanna L. Parish*

Bute Medical School, University of St Andrews, Bute Building, St Andrews, Fife KY16 9TS, UK

Viruses that maintain their genomes as extrachromosomal circular DNA molecules and establish infection in actively dividing cells must ensure retention of their genomes within the nuclear envelope in order to prevent genome loss. The loss of nuclear membrane integrity during mitosis dictates that paired host cell chromosomes are captured and organized by the mitotic spindle apparatus before segregation to daughter cells. This prevents inaccurate chromosomal segregation and loss of genetic material. A similar mechanism may also exist for the nuclear retention of extrachromosomal viral genomes or episomes during mitosis, particularly for genomes maintained at a low copy number in latent infections. It has been heavily debated whether such a mechanism exists and to what extent this mechanism is conserved among diverse viruses. Research over the last two decades has provided a wealth of information regarding the mechanisms by which specific tumour viruses evade mitotic and DNA damage checkpoints. Here, we discuss the similarities and differences in how specific viruses tether episomal genomes to host cell chromosomes during mitosis to ensure long-term persistence.

Keywords: viral persistence; segregation; DNA tumour virus; genome; mitosis

1. INTRODUCTION

While the specific mechanism of genome segregation during mitotic cellular division employed by each DNA virus studied has subtle or sometimes major distinctions, the overall theme of the way in which viruses have evolved to ensure genome persistence in dividing cells remains strikingly similar. Viral genomes are replicated along with the cellular DNA and are attached to host cell chromosomes during cellular division. This ensures retention in the nuclear envelope and in some cases may facilitate a roughly even distribution of episomal DNA molecules to each daughter cell (figure 1). To facilitate this mechanism of genome tethering, each virus encodes a DNA-binding protein, which specifically associates with repeated sequences within the viral genome. The viral DNA-binding protein then targets host cell proteins that themselves associate with mitotic chromatin, thus tethering viral genomes to the host cell DNA during mitotic segregation (figure 2). This elegant mechanism appears to have evolved to ensure viral persistence during low copy latent infections, and thus provides a powerful and novel antiviral target. The similarities and differences in the way in which different DNA tumour viruses have developed their own segregation mechanism will be discussed in this review.

2. EPSTEIN–BARR VIRUS

Epstein–Barr virus (EBV) is a human γ-herpesvirus (genus lymphocryptovirus) that persists benignly in approximately 90 per cent of individuals worldwide. In developing countries, infection occurs in early childhood and is generally asymptomatic. Owing to better hygiene standards, infection is delayed until early adolescence in developed countries where it can result in infectious mononucleosis (Rickinson et al. 2000). Persistent EBV infection is tightly linked to the development of several human cancers including Burkitt’s lymphoma, Hodgkin’s disease and nasopharyngeal carcinoma (Crawford 2001). Although EBV potently transforms cells in culture, it is known to persist in vivo not by immortalizing infected B cells, but by establishing a true latency in normal resting memory B cells (Thorley-Lawson 2005).

During a latent infection, the EBV genome is episomally maintained as a 165 kb double-stranded circular DNA molecule, where nine latent proteins including five EBV nuclear antigens (EBNA) and three latent membrane proteins are expressed. These proteins are required to stimulate proliferation of the host cell and maintain a stable viral copy number within dividing cells (Thorley-Lawson 2005). Replication of the viral genome is stimulated once per cell cycle (Adams 1987) and requires repeat sequences within the viral origin of replication OriP and the viral EBNA1 protein (Lupton & Levine 1985; Reisman et al. 1985; Yates et al. 1985, 2000; Middleton & Sugden 1992). OriP contains 20 high-affinity 18 bp EBNA1-binding sites within the family of repeats (FR) element and four low-affinity binding sites within the dyad symmetry (DS) element (Reisman et al. 1985). Through its specific affinity for sequences within OriP, EBNA1 is also essential for transcriptional control of viral enhancers and promoters (Reisman & Sugden 1986; Sugden & Warren 1989; Wysokenski & Yates 1989; Altmann et al. 2006), and the retention of the viral

* Author for correspondence (jlp10@st-andrews.ac.uk).
The viral genome partitioning function of EBNA1 has been directly attributed to its ability to associate with host cell chromosomes during mitosis. EBNA1 localizes to discrete foci during mitosis that colocalize with host cell mitotic chromosomes (Grogan et al. 1983; Petti et al. 1990). Deletion studies have demonstrated that three independent domains of EBNA1 are involved in mitotic chromosome binding. Each of these domains are rich in basic residues and it is suggested that these regions may assist in chromosomal attachment via interaction with histone H1 (Marechal et al. 1999). Further work has shown that EBNA1 targets the cellular protein EBNA1 binding protein 2 (EBP2) to facilitate genome partitioning (Wu et al. 2000; Kapoor et al. 2001; Kapoor & Frappier 2003). The interaction between EBNA1 and EBP2 was originally identified in a yeast two-hybrid screen (Shire et al. 1999), and the requirement of EBP2 for the association of EBNA1 with chromosomes and EBNA1-dependent segregation of FR-containing plasmids was demonstrated using a reconstituted yeast system (Kapoor et al. 2001; Kapoor & Frappier 2003). In addition, EBNA1 and EBP2 have been shown to colocalize on mitotic chromosomes in human cells and deletion of one of the chromosome-binding sites identified by Marechal et al. (1999) results in a loss of association of EBNA1 with EBP2 (Wu et al. 2000). Interestingly, it has been demonstrated that the association of human EBP2 with chromosomes is regulated by the Aurora family kinase member Aurora B (Kapoor et al. 2005). This suggests a role for the mitotic checkpoint regulator Aurora B in the partitioning of EBV genomes, although EBP2 itself is not thought to be a direct target of Aurora kinase.

In contrast to the studies described above, it has been suggested that EBNA1 associates directly with mitotic chromosomes in human cells independently of its association with EBP2 (Lindner & Sugden 2007). This interaction is proposed to be via an AT-hook motif within EBNA1 that binds to adenosine/thymidine (A/T)-rich DNA sequences (Sears et al. 2004). Similar to the EBP2-binding region within EBNA1, the two EBNA1 AT-hook motifs overlap with chromosomal binding regions described by Marechal et al. (1999), and it has been shown that the partitioning function of EBNA1 correlates with its AT-hook activity and not with EBP2.
binding (Sears et al. 2004). In support of this, fusion of the DNA binding and dimerization domain of EBNA1 that lacks the EBP2-binding region, with cellular proteins containing AT-hook motifs, supports wild-type levels of viral plasmid replication and partitioning (Altmann et al. 2006).

Mutant EBNA1 proteins that fail to activate transient replication of OriP-containing plasmids are also defective in genome tethering function (Kanda et al. 2001). Therefore, it has been suggested that EBNA1 functions to couple viral genome replication during S-phase to the subsequent tethering of replicated genomes to chromosomes during mitosis. In support of this, it has been demonstrated that replicated OriP-containing plasmids are spatially colocalized as pairs on mitotic chromosomes and that this positioning is essential for their non-random partitioning (Kanda et al. 2007; Nanbo et al. 2007). Nanbo et al. (2007) speculated that EBNA1 associates with chromosomal DNA during G1 and that replication of a subset of viral genomes is coincident with progression to the S-phase. This results in an association of the newly replicated EBV sister plasmids with the same or nearby sites on each sister chromatid where the cellular cohesin complex (Nasmyth 2005) may be required to hold the tethered EBV plasmids together. This model proposes that the replicated EBV sister plasmids are segregated to daughter cells as the sister chromatids separate at anaphase and offers an exciting twist to the specific mechanism EBV uses to maintain low copy number episomal genomes in latent and persistent viral infections.

3. RHADINOVIRUS

(a) Kaposi’s sarcoma-associated herpesvirus

Similar to EBV, Kaposi’s sarcoma-associated herpesvirus (KSHV; also known as human herpesvirus 8, HHV-8) is a γ-herpesvirus. KSHV belongs to the genus Rhadinovirus and is the only member of the genus known to infect humans. The incidence of KSHV infection is low in Asia, northern Europe, Australia and the Americas (less than 5%) but higher in Mediterranean countries (4–35%) and sub-Saharan Africa (20–70%) (Schulz et al. 2002). KSHV infection is typically asymptomatic in immunocompetent individuals. Nonetheless, KSHV is the causative agent of primary effusion myeloma, Castleman’s disease and Kaposi’s sarcoma (Moore & Chang 2001). Kaposi’s sarcoma, which is characterized by pigmented sarcomas of the skin, is often the presenting symptom of acquired immune deficiency syndrome (AIDS). In fact, KSHV was discovered by the analysis of DNA fragments from AIDS-associated Kaposi’s sarcoma (Chang et al. 1994).

The KSHV genome comprises a long unique region (140 kb) flanked by two terminal repeat (TR) regions, which consist of tandem repeats of 803 bps long (Russo et al. 1996). The number of repeated sequences varies between strains (Judd et al. 2000). During latent infection, only a relatively short portion (11 kb) of the viral episome is transcribed. These latent transcripts encode six proteins; viral cyclin D, latency-associated nuclear antigen 1 (LANA1/LANA), Kaposin A and B, viral FAS ligand interleukin-1B-converting enzyme inhibitory protein, and the viral homologue of interferon regulatory factor 3 (LANA2); and 12 pre-miRNAs (reviewed in Laurent et al. 2008). To date, 86 open reading frames (ORFs) have been identified and possibly more exist as further splice variants are discovered.

LANA protein is present in nearly all infected cells, and therefore, anti-LANA antibodies can be used as a marker of infection (Rainbow et al. 1997; Laney et al. 2006). LANA, encoded by ORF73, plays multiple roles in the viral life cycle and thus is the most extensively studied latent transcript. LANA is required for viral replication, episome maintenance and regulation of latent gene expression. It has been clearly demonstrated that LANA promotes progression through the cell cycle by interacting with p53, pRb and c-Myc pathways (Friborg et al. 1999; Radkov et al. 2000; Liu et al. 2007). Similar to EBV EBNA1 and the papillomavirus E2 protein (discussed below), disruption or depletion of LANA results in reduced episomal maintenance (Ye et al. 2004; Godfrey et al. 2005).

LANA facilitates viral DNA replication via a specific interaction of the C-terminal DNA-binding domain with two sites within the TR: LANA-binding site 1 (LBS1) and LANA-binding site 2 (LBS2) (Garber et al. 2002; Hu et al. 2002). Computational analysis shows that the C-terminus is similar in structure to the EBV EBNA1 DNA-binding domain (Grundhoff & Ganem 2003). In addition, the LBS1/2 regions are similar in organization to the EBV DS element and binding of LANA and EBNA1, respectively, is required for DNA replication (Rawlins et al. 1985; Yates et al. 1985; Polvino-Bodnar & Schaffer 1992; Garber et al. 2002; Hu et al. 2002; Lim et al. 2002; Hu & Renne 2005). It has recently been shown that LANA binds to host cell origin recognition complexes (ORCs) and may recruit ORCs to sites of latent origins of replication (Stedman et al. 2004; Verma et al. 2006).

Almost a decade ago, two independent research groups suggested a role for LANA in the tethering of viral episomes to host chromosomes during mitosis (Ballestas et al. 1999; Cotter & Robertson 1999). As previously mentioned, LANA binds to the TR via its C-terminus (Ballestas & Kaye 2001; Cotter et al. 2001; Komatsu et al. 2004). The residues within the C-terminus, which are required for TR DNA binding, have been mapped in some detail, and correspond to those required for EBNA1 DNA binding (Kelley-Clarke et al. 2007). The mechanism by which LANA associates with chromosomes remains to be elucidated. LANA has a punctate nuclear distribution in the presence of the KSHV genome or TR-containing plasmids but in the absence of TR DNA, LANA is distributed diffusely in the nucleus (Ballestas et al. 1999; Schwam et al. 2000). Although both the N- and C-termini can bind to chromosomes, it seems that LANA is recruited to TR DNA via binding of the C-terminal domain while the N-terminus tethers epismes to chromosomes by binding chromosome-associated proteins (Pirolt et al. 2001; Barbera et al. 2006).

Several cellular proteins have been implicated in the genome tethering mechanism of KSHV. Recruitment of LANA to mouse chromosomes has been shown to require methyl CpG-binding protein (MeCP2) and DEK (Krithivas et al. 2002). However, a more recent study illustrates that the LANA residues responsible for chromosome binding interact with histones H2A and H2B (Barbera et al. 2006). Perhaps MeCP2 and DEK, with their associated chromatin-modifying properties, facilitate LANA binding to nucleosomes.
(Bowen et al. 2004; Waldmann et al. 2004). In addition to the aforementioned proteins, LANA has also been shown to interact with Brd4, Brd2/Ring3, Histone H1 and nuclear mitotic apparatus protein (NuMA; Cotter & Robertson 1999; Ottinger et al. 2006; You et al. 2006; Si et al. 2008). In addition to the cellular proteins directly targeted by LANA, it has been shown that the cellular cohesin complex and the transcriptional insulator CCCTC-binding factor (CTCF) associate with sequences within the latency control region of KSHV genomes, and that together these factors play a role in the control of latent gene expression (Stedman et al. 2008). The authors also speculate that, similar to the related EBV, KSHV genomes may remain associated following replication and that genomes are actively segregated like host cell chromosomes by the regulation of cohesin association. Interestingly, CTCF has also been shown to associate with EBV episomes, although this is thought to be required for the transcriptional regulation of viral genes by facilitating chromatin domain organization, and not for genome maintenance per se (Chau et al. 2006; Day et al. 2007). It is clear that further research is required to dissect the contribution of individual cellular proteins to the maintenance of episomal KSHV genomes.

(b) Other ORF73-encoded proteins
Almost all γ2-herpesviruses encode homologous proteins from ORF73. The proteins vary greatly in length; KSHV LANA is one of the longest (1162 amino acids) while bovine herpesvirus 4 (BoHV-4) ORF73 is the shortest (253 amino acids). The acidic internal repeat region is the bovine herpesvirus 4 (BoHV-4) ORF73 is the shortest (253 amino acids). The acidic internal repeat region is the least conserved region and varies in length and in some species is completely absent (murine γ-herpesvirus 68 (MHV-68), rhesus rhadinovirus (RRV) and BoHV-4). Conversely, the N- and C-terminal regions of proteins translated from ORF73 are highly conserved (Burnside et al. 2006; Taus et al. 2007). Similar to LANA, herpesvirus saimiri (HVS) ORF73 inhibits p53 and pRb function and it has been shown that the expression of MHV-68 ORF73 results in decreased p53 stabilization (Borah et al. 2004; Forrest et al. 2007).

There is some evidence to suggest that the genome tethering function of proteins expressed from ORF73 is also conserved. HVS ORF73 has been shown to tether the viral genome to host chromosomes and facilitate episomal maintenance by binding to TR DNA (Collins et al. 2002; Verma & Robertson 2003; White et al. 2003). Furthermore, the C-terminus of HVS ORF73 is required for nuclear localization, a feature which is also characteristic of KSHV LANA (Hall et al. 2000). There have been a limited number of studies on MHV-68 ORF73; however, it has been demonstrated that ORF73 is required to establish and maintain latency (Fowler et al. 2003; Moorman et al. 2003). It has also been shown that LANA can regulate viral latency by inhibiting the replication and transcription activator protein (RTA), which is encoded by ORF50 and functions as a transcriptional activator of early and late lytic genes (Lan et al. 2004). Similarly, HSV ORF73 blocks RTA-mediated transactivation by direct inhibition of ORF50 expression (Schafer et al. 2003). RRV ORF73 also represses RTA-mediated transactivation, although the mechanism is unclear (DeWire & Damania 2005). This provides evidence that both HVS- and RRV ORF73-encoded proteins inhibit ORF50 function. Further evidence for conservation of the lytic switch mechanism is demonstrated by the fact that KSHV RTA can reactivate MHV-68 from latency (Rickabaugh et al. 2005).

4. PAPILLOMAVIRUS
Papillomaviruses are a diverse group of small DNA viruses that infect epithelial cells with numerous clinical outcomes. There are approximately 120 viral types described that infect mammals and birds with a high degree of species specificity. Of these, approximately 100 human papillomavirus (HPV) types have been defined, which infect the basal cells of either mucosal or cutaneous epithelia in a variety of biological niches (de Villiers et al. 2004). Once infection is established, papillomaviruses can persist in infected individuals for long periods of time and many types appear to have a latent life cycle where viral DNA can be detected in areas of healthy skin (Antonsson & Hansson 2002; Antonsson et al. 2003). HPV infection commonly causes benign tumours (warts and papillomas) but is often associated with malignant progression including cervical, anogenital or oropharyngeal carcinomas. HPVs are subdivided into five genera depending on the preferential site of infection and clinical outcome. The two largest HPV genera are the alpha and beta papillomaviruses and comprise 90 per cent of all known HPV types. The association of specific HPV types with carcinoma is used to further classify viral types. For example, within the alpha or genital/mucosal papillomavirus group, HPV types 6 and 11 are classified as low-risk and have little or no association with anogenital carcinoma whereas infection at the same site with high-risk HPVs, such as types 16 and 18, can result in malignant progression. In support of this, it has been shown that more than 99.7 per cent of cervical cancers contain high-risk HPV DNA with approximately 50 per cent of these containing HPV-16 DNA (Doorbar 2006).

All papillomaviruses contain an approximately 8000 bp double-stranded circular DNA genome that encodes eight or nine ORFs including six early ORFs (E1, E2, E4, E5, E6 and E7) and two late ORFs (L1 and L2). Upon infection of basal cells within the epidermis, the viral genome is established as a stable episome and maintained at a low copy number. Viral genomes are replicated along with the cellular DNA during the S-phase, which requires the viral E1 and E2 proteins. E2 is a multifunctional DNA-binding protein that specifically recognizes the consensus motif (AACC(G/N)CGGTT) (Dell et al. 2003), which is repeated multiple times in the non-coding regulatory region or long control region (LCR) of the viral genome. The association of E2 with binding motifs within this region is necessary for the recruitment of the E1 helicase, which in turn melts the origin of replication and recruits cellular proteins required for replication, such as replication protein A and DNA polymerase α primase (Masterson et al. 1998; Conger et al. 1999; Han et al. 1999; Loo & Melendy 2004). E2 also functions as a transcription factor and regulates the expression of the E6 and E7 viral oncoproteins by association with motifs within the LCR that lie close to the early promoter.

In addition to its role in viral genome replication and transcriptional regulation, E2 is required for the stable maintenance of viral genomes by facilitating an intricate segregation mechanism of viral genomes in dividing cells.
This mechanism has been extensively studied in both human and animal papillomaviruses with subtle differences between genera reported. Initial studies were carried out using bovine papillomavirus type 1 (BPV-1). The BPV-1 E2 protein associates with mitotic chromosomes throughout mitosis in a manner that requires sequences within the N-terminal transactivation domain of E2 (Skidopoulos & McBride 1998; Ilves et al. 1999; Bastien & McBride 2000; Abroi et al. 2004). From this, it was hypothesized that the E2 protein from all papillomavirus types forms a link between viral genomes, specifically bound by the C-terminal DNA-binding domain of E2, and mitotic chromosomes, bound by the N-terminal transactivation domain of E2 via interaction with cellular chromatin-associated protein(s). This is consistent with the segregation mechanism of the other DNA viruses described in this review, and has remained the common theme for all HPVs tested with some subtle differences.

While BPV-1 E2 stably associates with chromosomes throughout mitosis in numerous random foci, the E2 proteins from the alpha group (e.g. HPV-11, -16, -31 and -57) have been shown to stably interact with mitotic chromosomes only in early (prophase) and late (telophase) mitosis, but not at the point of chromosomal separation (anaphase) (Oliveira et al. 2006; Donaldson et al. 2007). However, it was noted that the interaction of these E2 proteins with chromosomes throughout mitosis can be observed if cells are pre-extracted prior to fixation (Oliveira et al. 2006), suggesting that the interaction of alpha group E2 proteins with mitotic chromosomes may occur but is highly dynamic and unstable. The HPV-8 E2 protein displays further differences in its mitotic localization pattern in that it appears to associate with chromosomes only at sites very close to the point of attachment of the mitotic spindle. This is potentially in agreement with a study by Van Tine et al. (2004) which showed that plasmids containing E2-binding sites are localized in foci adjacent to the spindle attachment site in an HPV-11 E2-dependent manner, although further studies from the same group have suggested that the HPV-11 E2 protein itself associates with the spindles during mitosis (Van Tine et al. 2004; Dao et al. 2006). However, the biological significance of this remains unclear.

The search for the specific mechanism by which E2 tethers viral genomes to mitotic chromosomes has been long standing, and the cellular proteins that E2 targets to facilitate segregation of genomes remain unclear. It has been reported that the bromodomain family member Brd4 is required for the attachment of HPV-31, HPV-16 and BPV-1 E2 to mitotic DNA (You et al. 2004; Baxter et al. 2005; Abbate et al. 2006). In support of this, Brd4 and BPV-1 E2 colocalize at punctate foci on mitotic chromosomes and overexpression of the C-terminal domain (Brd4–CTD) or a small peptide shown to block the interaction between E2 and Brd4 prevents the association of E2 with host cell chromosomes and enhances genome loss in BPV-1-transformed cells (McPhillips et al. 2005; You et al. 2005; Abbate et al. 2006). While these data suggest a role for Brd4 in the tethering of E2 to host cell chromosomes, it has also been demonstrated that Brd4 associates with E2 to facilitate E2-dependent transcriptional regulation (Ilves et al. 2006; McPhillips et al. 2006; Schweiger et al. 2006; Senechal et al. 2007; Wu & Chiang 2007), and that Brd4 is not required for the maintenance of all papillomavirus types (McPhillips et al. 2006). In support of this, mutant E2 proteins that fail to associate with Brd4 and do not support stable genome maintenance are unable to activate transcription (Baxter et al. 2005; Abbate et al. 2006; Ilves et al. 2006). This suggests that inhibition of Brd4 association is unlikely to only affect chromosome attachment, but will also alter other important functions of E2 required for the replication and maintenance of viral genomes. Furthermore, depletion of Brd4 using RNA interference has no effect on the association of BPV-1 and HPV-11 E2 proteins with mitotic chromosomes (Parish et al. 2006a). Put together, these data certainly suggest a role for Brd4 in the segregation of at least some papillomavirus types but its necessity in this process remains unresolved at present.

Other quests to isolate E2-associated cellular proteins have isolated new candidates that are involved in the segregation of papillomavirus genomes during mitosis. An interaction between HPV-16 E2 and the topoisomerase II-binding protein (TopBP1) has been described and shown to enhance the transcriptional and replication activities of E2 (Boner et al. 2002). More recently, TopBP1 has been hypothesized to be involved in viral genome segregation and shown to regulate the association of E2 with chromatin. E2 and TopBP1 colocalize during late mitosis and it is suggested that TopBP1 may be targeted by HPV-16 E2 to facilitate mitotic tethering (Donaldson et al. 2007).

Using a yeast two-hybrid system to screen a yeast cDNA library, an interaction between BPV-1 E2 and the DEAH family DNA helicase chromosome loss 1 (Chl1) was isolated (Parish et al. 2006a). Chl1 is required for the efficient segregation of chromosomes (Gerring et al. 1990) and studies on the human homologue, Chl-related 1 (ChlR1), have demonstrated a role in sister chromatid cohesion (Parish et al. 2006b; Inoue et al. 2007). The E2 proteins from BPV-1 and HPV types 11 and 16 have been shown to interact with ChlR1, demonstrating conservation of this interaction between genera. A mutant of BPV-1 E2 (W130R) has been isolated that no longer associates with ChlR1 but retains Brd4 binding, transcriptional activation and E2-dependent viral replication functions (Parish et al. 2006a). Although viral genomes that encode E2 W130R are able to transiently replicate in mouse fibroblasts, these genomes are not stably maintained, indicating that ChlR1 interaction is required for the maintenance of genomes over time and questions the necessity for Brd4 interaction in the tethering of PV genomes. This was confirmed by depletion of ChlR1, which disrupts the association of E2 with mitotic chromosomes. However, association is unaffected by the depletion of Brd4. Interestingly, E2 and ChlR1 do not colocalize during mitosis (Parish et al. 2006a), but a robust interaction is observed during the S-phase (A. Saade & J. L. Parish 2008, unpublished data) indicating that ChlR1 is required for the loading of E2 and viral genomes onto chromatin during the S-phase, possibly during cohesion establishment, and not for the direct tethering of genomes to chromosomes during mitosis. It remains to be seen whether ChlR1, Brd4 and/or TopBP1 act in concert to facilitate the segregation of viral genomes and whether these cellular proteins contribute to a cellular pathway required for the accurate segregation of chromosomes to daughter cells.
Table 1. Summary of the DNA viruses that actively segregate genomes during mitosis and the reported mechanisms by which this is achieved.

| virus     | genome size (base pairs) | viral protein required for genome tethering | chromosomal association pattern during mitosis | suggested associated cellular protein(s) that facilitate segregation |
|-----------|--------------------------|-------------------------------------------|-----------------------------------------------|------------------------|
| EBV       | 165 000                  | EBNA-1                                    | paired foci randomly associated with chromosomes random speckles | Histone H1 and EBP2 |
| KSHV      | 140 000                  | LANA                                      | paired foci randomly associated with chromosomes random speckles | MeCP2, DEK, Brd2/4 histones H1, H2A and H2B, NuMA |
| papillomavirus | 8 000               | E2                                        | random speckles or foci near spindle attachment region | Brd4, ChlR1 and TopBP1 |

5. CONCLUSIONS
It is clear that many DNA tumour viruses have evolved complex mechanisms to ensure genome persistence (as summarized in table 1). There is much to be done to clearly define the exact mechanism each virus employs. Whether viruses that maintain genomes at low copy number have a different mechanism of genome tethering from those maintained at high copy number needs to be determined. Viruses that maintain few episomal genomes per cell may ensure that plasmids are not tethered to a single chromosome or multiple chromosomes that are segregated to one daughter cell. Future studies that elucidate such a mechanism will be fascinating. The importance of specific cellular proteins that are targeted to facilitate genome tethering must also be clearly defined. Nonetheless, the current depth of understanding allows us to see the common themes that have evolved to ensure the maintenance of episomally maintained genomes of vastly different sizes from diverse viral types. It is clear that all the viral types discussed in this review encode a protein that functions to tether viral genomes to host cell chromosomes during mitosis. This viral protein is a DNA-binding protein that specifically associates with consensus-binding sites within the viral genome, meanwhile associating with mitotic chromosomes. The association of these proteins with mitotic chromosomes can either be direct or indirect, mediated by association with host cell chromatin-bound proteins.

While the specific proteins each virus targets to mediate genome tethering are diverse, some common themes exist. For example, both KSHV LANA and papillomavirus E2 proteins have been shown to associate with bromodomain proteins, and both LANA and EBV EBNA1 proteins associate with components of the core histone. The involvement of cohesin in the segregation of viral genomes also seems to be consistent between different viral types. Cohesin associates with KSHV genomes, and EBV genomes are known to remain paired following replication. In addition, the tethering of papillomavirus genomes requires the cohesin establishment factor ChlR1, suggesting that this subset of viruses also target the cohesin establishment pathway.

Numerous studies have shown that the disruption of viral genome tethering during mitosis results in a loss of viral genomes over time. This opens the door for the design of novel antiviral therapeutics. In order for this to be successful, several factors should be carefully considered. Small molecules may need to be designed that affect only the tethering and not the replication or transcriptional functions of the viral protein(s) targeted. Such a small molecule will ensure that viral oncoproteins are held under strict transcriptional control and episomal genomes replicate normally. This will prevent any possibility of forced integration, as has been suggested for papillomaviruses (Lusky & Botchan 1985; Lambert & Howley 1988; Schiller et al. 1989; Taylor et al. 2003), although the potential risk of integration owing to aberrant replication needs to be further studied for a true link to be identified. Nonetheless, the design of novel and highly specific antiviral therapeutics that inhibit episomal genome tethering resulting in genome loss through rounds of cell division is an interesting concept and should be pursued.

Funding is provided by a Royal Society University Research Fellowship to J.L.

REFERENCES
Abbate, E. A., Voitenleiner, C. & Botchan, M. R. 2006 Structure of the papillomavirus DNA-tethering complex E2: Brd4 and a peptide that ablates HPV chromosomal association. Mol. Cell 24, 877–889. (doi:10.1016/j.molcel.2006.11.002)
Abroi, A., Ilves, I., Kivi, S. & Ustav, M. 2004 Analysis of chromatin attachment and partitioning functions of bovine papillomavirus type 1 E2 protein. J. Virol. 78, 2100–2113. (doi:10.1128/JVI.78.4.2100-2113.2004)
Adams, A. 1987 Replication of latent Epstein–Barr virus genomes in Raji cells. J. Virol. 61, 1743–1746.
Altmann, M., Pich, D., Russ, R., Wang, J., Sugden, B. & Hammerschmidt, W. 2006 Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc. Natl. Acad. Sci. USA 103, 14188–14193. (doi:10.1073/pnas.0605985103)
Antonsson, A. & Hansson, B. G. 2002 Healthy skin of many animal species harbors papillomaviruses which are closely related to their human counterparts. J. Virol. 76, 12537–12542. (doi:10.1128/JVI.76.24.12537-12542.2002)
Antonsson, A., Erfurt, C., Hazard, K., Holmgren, V., Simon, M., Kataoka, A., Hossain, S., Hakangard, C. & Hansson, B. G. 2003 Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J. Gen. Virol. 84, 1881–1886. (doi:10.1099/vir.0.18836-0)
Ballestas, M. E. & Kaye, K. M. 2001 Kaposis sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA. J. Virol. 75, 3250–3258. (doi:10.1128/JVI.75.7.3250-3258.2001)
Ballestas, M. E., Chatis, P. A. & Kaye, K. M. 1999 Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284, 641–644. (doi:10.1126/science.284.5414.641)
Barbera, A. J., Chodaparambil, J. V., Kelley-Clarke, B., Joukov, V., Walter, J. C., Lugner, K. & Kaye, K. M. 2006

Proc. R. Soc. B (2009)
The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. Science **311**, 856–861. (doi:10.1126/science.1120541)

Bastien, N. & McBride, A. A. 2000 Interaction of the papillomavirus E2 protein with mitotic chromosomes. Virology **270**, 124–134. (doi:10.1006/viro.2000.0265)

Barr, M. K., Phillips, M. G., Ozato, K. & McBride, A. A. 2005 The mitotic chromosome binding activity of the papillomavirus E2 protein correlates with interaction with the cellular chromosomal protein, Brd4. J. Virol. **79**, 4806–4818. (doi:10.1128/JVI.79.8.4806-4818.2005)

Boner, W., Taylor, E. R., Tsirimonaki, E., Yamane, K., Borah, S., Verma, S. C. & Robertson, E. S. 2004 ORF73 of bovine papillomavirus inhibits viral replication through repression of ORF50/RTA transcriptional activation. J. Virol. **79**, 3127–3138. (doi:10.1128/JVI.79.5.3127-3138.2005)

Bowe, N. J., Palmer, M. B. & Wade, P. A. 2004 The localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus. J. Virol. **80**, 4792–4800. (doi:10.1128/JVI.80.10.4792-4800.2006)

Dao, L. D., Duffy, A., Van Tine, B. A., Wu, S. Y., Chang, C. M., Broker, T. R. & Chow, L. T. 2006 Dynamic localization of the human papillomavirus type 11 origin binding protein E2 through mitosis while in association with the spindle apparatus. J. Virol. **80**, 4792–4800. (doi:10.1128/JVI.80.10.4792-4800.2006)

Day, L., Chau, C. M., Nebozinh, M., Rennekamp, A. J., Showe, M. & Lieberman, P. M. 2007 Chromatin profiling of Epstein–Barr virus latency control region. J. Virol. **81**, 6389–6401. (doi:10.1128/JVI.02172-06)

De Villiers, E. M., Faquist, C., Broker, T. R., Bernard, H. U. & zur Hausen, H. 2004 Classification of papillomaviruses. Virology **324**, 17–27. (doi:10.1016/j.virol.2004.03.033)

DeWire, S. M. & Damian, B. 2005 The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of ORF50/RTA transcriptional activation. J. Virol. **79**, 3127–3138. (doi:10.1128/JVI.79.5.3127-3138.2005)

DeWire, S. M. & Damian, B. 2005 The latency-associated nuclear antigen of rhesus monkey rhadinovirus inhibits viral replication through repression of ORF50/RTA transcriptional activation. J. Virol. **79**, 3127–3138. (doi:10.1128/JVI.79.5.3127-3138.2005)

Donaldson, M. S., Boner, W. & Morgan, I. M. 2007 TopBP1 regulates human papillomavirus type 16 E2 interaction with chromatin. J. Virol. **81**, 4338–4342. (doi:10.1128/JVI.02353-06)

Doorbar, J. 2006 Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.) **110**, 525–541. (doi:10.1042/CS20050369)

Forrest, J. C., Paden, C. R., Allen III, R. D., Collins, J. & Speck, S. H. 2007 ORF73-null murine gammaherpesvirus 68 reveals roles for mLANA and p53 in virus replication. J. Virol. **81**, 11967–11971. (doi:10.1128/JVI.00011-07)

Fowler, P., Marques, S., Simas, J. P. & Efstathiou, S. 2003 ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J. Gen. Virol. **84**, 3405–3416. (doi:10.1099/vir.0.15954-0)

Friborg, J., Kong, W.-P., Hottiger, M. O. & Nabel, G. J. 1999 p53 inhibition by the LANA protein of KSHV protects against cell death. Nature **402**, 889–894.

Garber, A. C., Hu, J. & Renne, R. 2002 Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. J. Biol. Chem. **277**, 4027–401–41. (doi:10.1074/jbc.M203489200)

Gerring, S. L., Spencer, F. & Hieter, P. 1990 The CHL1 gene product of Saccharomyces cerevisiae is important for chromosome transmission and normal cell cycle progression in G2/M. EMBO J. **9**, 4347–4358.

Godfrey, A., Anderson, J., Papanastasiou, A., Takeuchi, Y. & Bosshoff, C. 2005 Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood **105**, 2510–2518. (doi:10.1182/blood-2004-08-3052)

Grogan, E. A., Summers, W. P., Dowling, S., Shedd, D., Gradoville, L. & Miller, G. 1983 Two Epstein–Barr viral nuclear neonautigens distinguished by gene transfer, serology, and chromosome binding. Proc. Natl Acad. Sci. USA **80**, 7650–7653. (doi:10.1073/pnas.80.24.7650)

Grundhoff, A. & Ganem, D. 2003 The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids. J. Virol. **77**, 2779–2783. (doi:10.1128/JVI.77.4.2779-2783.2003)

Hall, K. T., Giles, M. S., Goodwin, D. J., Calderwood, M. A., Markham, A. F. & Whitehouse, A. 2000 Characterization of the herpesvirus saimiri ORF73 gene product. J. Gen. Virol. **81**, 2633–2658.

Han, Y., Loo, Y. M., Milletto, K. T. & Melendy, T. 1999 Interactions of the papovavirus DNA replication initiating
proteins, bovine papillomavirus type 1 E1 and simian virus 40 large T antigen, with human replication protein A. J. Virol. 73, 4899–4907.

Hu, J. & Renne, R. 2005 Characterization of the minimal replicator of Kaposi's sarcoma-associated herpesvirus latent origin. J. Virol. 79, 2637–2642. (doi:10.1128/JVI.79.4.2637-2642.2005)

Hu, J., Garber, A. C. & Renne, R. 2002 The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J. Virol. 76, 11677–11687. (doi:10.1128/JVI.76.22.11677-11687.2002)

Ilves, I., Kivi, S. & Ustav, M. 1999 Long-term epimodal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites. J. Virol. 73, 4404–4412.

Ilves, I., Maenets, K., Silla, T., Janikson, K. & Ustav, M. 2006 Brd4 is involved in multiple processes of the bovine papillomavirus type 1 life cycle. J. Virol. 80, 3660–3665. (doi:10.1128/JVI.80.7.3660-3665.2006)

Inoue, A., Li, T., Roby, S. K., Valentine, M. B., Inoue, M., Boyd, K., Kidd, V. J. & Lahti, J. M. 2007 Loss of Chk1 helicase in mouse causes lethality due to the accumulation of aneuploid cells generated by cohesion defects and placental malformation. Cell Cycle 6, 1646–1654.

Judde, J. G. et al. 2000 Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J. Natl Cancer Inst. 92, 729–736. (doi:10.1093/jnci/92.9.729)

Kanda, T., Otter, M. & Wahl, G. M. 2001 Coupling of mitotic chromosome tethering and replication competence in Epstein–Barr virus-based plasmids. Mol. Cell. Biol. 21, 3576–3588. (doi:10.1128/MCB.21.10.3576-3588.2001)

Kanda, T., Kamiya, M., Maruo, S., Iwakiri, D. & Takada, K. 2007 Symmetrical localization of extrachromosomally replicating viral genomes on sister chromatids. J. Cell Sci. 120, 1529–1539. (doi:10.1242/jcs.03434)

Kapoor, P. & Frappier, L. 2003 EBNA1 partitions Epstein–Barr virus plasmids in yeast cells by attaching to human EBNA1-binding protein 2 on mitotic chromosomes. J. Virol. 77, 6946–6956. (doi:10.1128/JVI.77.12.6946-6956.2003)

Kapoor, P., Shire, K. & Frappier, L. 2001 Reconstitution of Epstein–Barr virus–based plasmid partitioning in budding yeast. EMBO J. 20, 222–230. (doi:10.1093/emboj/20.1.222)

Kapoor, P., Lavoie, B. D. & Frappier, L. 2005 EBP2 plays a key role in Epstein–Barr virus mitotic segregation and is regulated by Aurora family kinases. Mol. Cell. Biol. 25, 4934–4945. (doi:10.1128/MCB.25.12.4934-4945.2005)

Kelley-Clarke, B., Ballestas, M. E., Srivivasan, V., Barbera, A. J., Komatsu, T., Harris, T.-A., Kazanjian, M. & Kaye, K. M. 2007 Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. J. Virol. 81, 4348–4356. (doi:10.1128/JVI.01289-06)

Komatsu, T., Ballestas, M. E., Barbera, A. J., Kelley-Clarke, B. & Kaye, K. M. 2004 KSHV LANA1 binds DNA as an oligomer and residues N-terminal to the oligomerization domain are essential for DNA binding, replication, and episome persistence. Virology 319, 225–236. (doi:10.1016/j.virology.2003.11.002)

Krithivas, A., Fujimuro, M., Weidner, M., Young, D. B. & Hayward, S. D. 2002 Protein interactions targeting the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus to cell chromosomes. J. Virol. 76, 11596–11604. (doi:10.1128/JVI.11596-11604.2002)

Lambert, P. F. & Howley, P. M. 1988 Bovine papillomavirus type 1 E1 replication-defective mutants are altered in their transcriptional regulation. J. Virol. 62, 4009–4015.

Laney, A. S., Peters, J. S., Manzi, S. M., Kingsley, L. A., Chang, Y. & Moore, P. S. 2006 Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. J. Clin. Microbiol. 44, 3734–3741. (doi:10.1128/JCM.00191-06)

Langle-Rouault, F., Patzel, V., Benavente, A., Taillez, M., Silvestre, N., Bompard, A., Szczakel, G., Jacobs, E. & Rittner, K. 1998 Up to 100-fold increase of apparent gene expression in the presence of Epstein–Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids. J. Virol. 72, 6181–6185.

Lan, K., Kuppers, D. A., Verma, S. C. & Robertson, E. S. 2004 Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting RTA: a potential mechanism for virus-mediated control of latency. J. Virol. 78, 6585–6594. (doi:10.1128/JVI.78.20.6585-6594.2004)

Laurent, C., Meggetto, F. & Broussset, P. 2008 Human herpesvirus 8 infections in patients with immunodeficiencies. Hum. Pathol. 39, 983–993. (doi:10.1016/j.humpath.2008.02.010)

Lim, C., Sohn, H., Lee, D., Gwack, Y. & Choe, J. 2002 Functional dissection of latency-associated nuclear antigen I of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome. J. Virol. 76, 10320–10331. (doi:10.1128/JVI.76.20.10320-10331.2002)

Lindner, S. E. & Sugden, B. 2007 The plasmid replicon of Epstein–Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 58, 1–12. (doi:10.1016/j.plasmid.2007.01.003)

Liu, J., Martin, H. J., Liao, G. & Hayward, S. D. 2007 The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J. Virol. 81, 10451–10459. (doi:10.1128/JVI.00804-07)

Loo, Y. M. & Melendez, T. 2004 Recruitment of replication protein A by the papillomavirus E1 protein and modulation by single-stranded DNA. J. Virol. 78, 1605–1615. (doi:10.1128/JVI.78.4.1605-1615.2004)

Lupinton, S. & Levine, A. J. 1985 Mapping genetic elements of Epstein–Barr virus that facilitate extrachromosomal persistence of Epstein–Barr virus–derived plasmids in human cells. Mol. Cell. Biol. 5, 2533–2542.

Lusky, M. & Botchan, M. R. 1985 Genetic analysis of bovine papillomavirus type 1 trans-acting replication factors. J. Virol. 53, 955–965.

Marechal, V., Dehee, A., Chiiki-Brachet, R., Piolot, T., Coppey-Moisan, M. & Nicolas, J. C. 1999 Mapping EBNA-1 domains involved in binding to metaphase chromosomes. J. Virol. 73, 4385–4392.

Masterson, P. J., Stanley, M. A., Lewis, A. P. & Romanos, M. A. 1998 A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase alpha-primase p68 subunit. J. Virol. 72, 7407–7419.

McPhillips, M. G., Ozato, K. & McBride, A. A. 2005 Interaction of bovine papillomavirus E2 protein with Brd4 stabilizes its association with chromatin. J. Virol. 79, 8920–8932. (doi:10.1128/JVI.79.14.8920-8932.2005)

McPhillips, M. G., Oliveira, J. G., Spinder, J. E., Mitra, R. & McBride, A. A. 2006 Brd4 is required for E2-mediated transcriptional activation but not genome partitioning of all papillomaviruses. J. Virol. 80, 9350–9353. (doi:10.1128/JVI.01105-06)
Middleton, T. & Sugden, B. 1992 EBNA1 can link the enhancer element to the initiator element of the Epstein–Barr virus plasmid origin of DNA replication. *J. Virol.* **66**, 489–495.

Middleton, T. & Sugden, B. 1994 Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein–Barr virus replication protein EBNA1. *J. Virol.* **68**, 4067–4071.

Moore, P. S. & Chang, Y. 2001 Molecular virology of Kaposi’s sarcoma-associated herpesvirus. *Phil. Trans. R. Soc. B* **356**, 499–516. (doi:10.1098/rstb.2000.0777)

Moorman, N. J., Willer, D. O. & Speck, S. H. 2003 The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. *J. Virol.* **77**, 10 295–10 303. (doi:10.1128/JVI.77.19.10295-10303.2003)

Nanbo, A., Sugden, A. & Sugden, B. 2007 The coupling of EBNA1 to clustered sites in the plasmid maintenance region. *Cell* **42**, 859–868. (doi:10.1016/0092-8674(85)90282-X)

Reisman, D. & Sugden, B. 1986 Transactivation of an Epstein–Barr viral transcriptional enhancer by the Epstein–Barr virus nuclear antigen 1. *Mol. Cell. Biol.* **6**, 3838–3846.

Reisman, D., Yates, J. & Sugden, B. 1985 A putative origin of replication of plasmids derived from Epstein–Barr virus is composed of two cis-acting components. *Mol. Cell. Biol.* **5**, 1822–1832.

Rickabaugh, T. M., Brown, H. J., Wu, T.-T., Song, M. J., Hwang, S., Deng, H., Mitsouras, K. & Sun, R. 2005 Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 RTA reactivates murine gammaherpesvirus 68 from latency. *J. Virol.* **79**, 3217–3222. (doi:10.1128/JVI.79.5.3217-3222.2005)

Rickinson, A. B., Callan, M. F. C. & Annels, N. E. 2000 T-cell memory: lessons from Epstein–Barr virus infection in man. *Phil. Trans. R. Soc. Lond. B* **355**, 391–400. (doi:10.1098/rstb.2000.0579)

Russo, J. J. et al. 1996 Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). *Proc. Natl Acad. Sci. USA* **93**, 14 862–14 867. (doi:10.1073/pnas.93.25.14862)

Schafer, A., Lengerfelder, D., Grillhoss, C., Wieser, C., Fleckenstein, B. & Ensser, A. 2003 The latency-associated nuclear antigen homolog of herpesvirus saimiri inhibits lytic virus replication. *J. Virol.* **77**, 5911–5925. (doi:10.1128/JVI.77.17.5911-5925.2003)

Schiller, J. T., Kleiner, E., Androphy, E. J., Lowy, D. R. & Pfister, H. 1989 Identification of bovine papillomavirus E1 mutants with increased transforming and transcriptional activity. *J. Virol.* **63**, 1775–1782.

Schulz, T. F., Sheldon, J. & Greensill, J. 2002 Kaposi’s sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). *Virus Res.* **82**, 115–126. (doi:10.1016/S1090-720X(01)00394-X)

Schwam, D. R., Luciano, R. L., Mahajan, S. S., Wong, L. & Wilson, A. C. 2000 Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. *J. Virol.* **74**, 8532–8540. (doi:10.1128/JVI.74.18.8532-8540.2000)

Schweiger, M. R., You, J. & Howley, P. M. 2006 Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. *J. Virol.* **80**, 4276–4285. (doi:10.1128/JVI.80.9.4276-4285.2006)

Sears, J., Ujihara, M., Wong, S., Ott, C., Middeldorp, J. & Aiyar, A. 2004 The amino terminus of Epstein–Barr virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. *J. Virol.* **78**, 11 487–11 505. (doi:10.1128/JVI.78.21.11487-11505.2004)

Senechal, H., Poirier, G. G., Coulombe, B., Laimins, L. A. & Archambault, J. 2007 Amino acid substitutions that specifically impair the transcriptional activity of papillomavirus E2 affect binding to the long isoform of Brd4. *Virology* **358**, 10–17. (doi:10.1016/j.virol.2006.08.035)

Shire, K., Cecarelli, D. F. J., Avolio-Hunter, T. M. & Frappier, L. 1999 EB2p, a human protein that interacts with sequences of the Epstein–Barr virus nuclear antigen 1 important for plasmid maintenance. *J. Virol.* **73**, 2587–2595.

Si, H., Verma, S. C., Lampson, M. A., Cai, Q. & Robertson, E. S. 2008 Kaposi’s sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic

**Proc. R. Soc. B** (2009)
apparatus protein to regulate genome maintenance and segregation. *J. Virol.* 82, 6734–6746. (doi:10.1128/JVI.00342-08)

Skiodoulos, M. H. & McBride, A. A. 1998 Bovine papillomavirus type 1 genomes and the E2 transactivator protein are closely associated with mitotic chromatin. *J. Virol.* 72, 2079–2088.

Stedman, W., Deng, Z., Lu, F. & Lieberman, P. M. 2004 ORC, MCM, and histone hyperacetylation at the Kaposi’s sarcoma-associated herpesvirus latent replication origin. *J. Virol.* 78, 12 566–12 575. (doi:10.1128/JVI.78.22.12566-12575.2004)

Stedman, W., Kang, H., Lin, S., Kissil, J. L., Bartolomei, M. S. & Lieberman, P. M. 2008 Cohesins localize with CTCF at the KSHV latency control region and at cellular c-Myc and H19/Igf2 insulators. *EMBO J.* 27, 654–666. (doi:10.1038/emboj.2008.1)

Sugden, B. & Warren, N. 1989 A promoter of Epstein–Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. *J. Virol.* 63, 2644–2649.

Taus, N. S., Herndon, D. R., Traul, D. L., Stewart, J. P., Ackermann, M., Li, H., Knowles, D. P., Lewis, G. S. & Brayton, K. A. 2007 Comparison of ovine herpesvirus 2 genomes isolated from domestic sheep (*Ovis aries*) and a clinically affected cow (*Bos bovis*). *J. Gen. Virol.* 88, 40–45. (doi:10.1099/vir.0.82285-0)

Taylor, E. R., Dornan, E. S., Boner, W., Connolly, J. A., McNair, S., Kannouche, P., Lehmann, A. R. & Morgan, I. M. 2003 The fidelity of HPV16 E1/E2-mediated DNA replication. *J. Biol. Chem.* 278, 52 223–52 230. (doi:10.1074/jbc.M308779200)

Thorlaxson, L. T. 2004 Human papillomavirus (HPV) origin-binding protein with Brd4 tethers the viral DNA to host mitotic chromosomes. *Cell* 117, 349–360. (doi:10.1016/S0092-8674(04)00402-7)

Van Tine, B. A., Dao, L. D., Wu, S. Y., Sonbuchner, T. M., Lin, B. Y., Zou, N., Chiang, C. M., Broker, T. R. & Chow, L. T. 2004 Human papillomavirus (HPV) origin-binding protein associates with mitotic spindles to enable viral DNA partitioning. *Proc. Natl Acad. Sci. USA* 101, 4030–4035. (doi:10.1073/pnas.0306848101)

Verma, S. C. & Robertson, E. S. 2003 ORF73 of herpesvirus saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. *J. Virol.* 77, 12 494–12 506. (doi:10.1128/JVI.77.23.12494-12506.2003)

Verma, S. C., Choudhuri, T., Kaul, R. & Robertson, E. S. 2006 Latency-associated nuclear antigen (LANA) of Kaposi’s sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. *J. Virol.* 80, 2243–2256. (doi:10.1128/JVI.80.5.2243-2256.2006)

Waldmann, T., Scholten, I., Kappes, F., Hu, H. G. & Knippers, R. 2004 The DEK protein: an abundant and ubiquitous constituent of mammalian chromatin. *Gene* 341, 1–9. (doi:10.1016/j.gene.2004.08.029)

White, R. E., Calderwood, M. A. & Whitehouse, A. 2003 Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence. *J. Gen. Virol.* 84, 3393–3403. (doi:10.1099/vir.0.19387-0)

Wu, S. Y. & Chiang, C. M. 2007 The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. *J. Biol. Chem.* 282, 13 141–13 145. (doi:10.1074/jbc.R700001200)

Wu, H., Ceccarelli, D. F. & Frappier, L. 2000 The DNA segregation mechanism of Epstein–Barr virus nuclear antigen 1. *EMBO Rep.* 1, 140–144. (doi:10.1039/embo-reports/kvd026)

Wysokinski, D. A. & Yates, J. L. 1989 Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein–Barr virus. *J. Virol.* 63, 2657–2666.

Yates, J. L., Warren, N. & Sugden, B. 1985 Stable replication of plasmids derived from Epstein–Barr virus in various mammalian cells. *Nature* 313, 812–815. (doi:10.1038/313812a0)

Yates, J. L., Camiolo, S. M. & Bashaw, J. M. 2000 The minimal replicator of Epstein–Barr virus oriP. *J. Virol.* 74, 4512–4522. (doi:10.1128/JVI.74.10.4512-4522.2000)

Ye, F.-C., Zhou, F.-C., Yoo, S. M., Xie, J.-P., Browning, P. J. & Gao, S.-J. 2004 Disruption of Kaposi’s sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. *J. Virol.* 78, 11 121–11 129. (doi:10.1128/JVI.78.20.11121-11129.2004)

You, J., Croyle, J. L., Nishimura, A., Ozato, K. & Howley, P. M. 2004 Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. *Cell* 117, 349–360. (doi:10.1016/S0092-8674(04)00402-7)

You, J., Schweiger, M. R. & Howley, P. M. 2005 Inhibition of E2 binding to Brd4 enhances viral genome loss and phenotypic reversion of bovine papillomavirus-transformed cells. *J. Virol.* 79, 14 956–14 961. (doi:10.1128/JVI.79.23.14956-14961.2005)

You, J., Sririnivasan, V., Denis, G. V., Harrington Jr, W. J., Ballestas, M. E., Kaye, K. M. & Howley, P. M. 2006 Kaposi’s sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. *J. Virol.* 80, 8909–8919. (doi:10.1128/JVI.00502-06)